| 3rd May 2022 3:00 pm |
RNS |
Total Voting Rights |
| 29th Apr 2022 5:30 pm |
RNS |
Result of AGM |
| 29th Apr 2022 7:05 am |
RNS |
AstraZeneca plans new R&D centre in Massachusetts |
| 29th Apr 2022 7:00 am |
RNS |
First quarter 2022 results |
| 28th Apr 2022 7:00 am |
RNS |
Ultomiris approved in the US for adults with gMG |
| 27th Apr 2022 7:00 am |
RNS |
Enhertu granted BTD for HER2-low breast cancer |
| 25th Apr 2022 7:00 am |
RNS |
Tremelimumab US Priority Review for Imfinzi combo |
| 19th Apr 2022 7:00 am |
RNS |
Enhertu granted Priority Review for HER2m NSCLC |
| 1st Apr 2022 3:00 pm |
RNS |
Total Voting Rights |
| 29th Mar 2022 7:00 am |
RNS |
Ondexxya approved in Japan for FXai reversal |
| 28th Mar 2022 7:00 am |
RNS |
Evusheld approved in the EU for COVID-19 |
| 25th Mar 2022 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 24th Mar 2022 6:00 pm |
RNS |
Evusheld Positive EU CHMP Opinion |
| 24th Mar 2022 7:00 am |
RNS |
Update on CALLA Phase III trial for Imfinzi |
| 23rd Mar 2022 11:00 am |
RNS |
Notice of AGM |
| 17th Mar 2022 7:00 am |
RNS |
Settlement of patent litigation for Ultomiris |
| 14th Mar 2022 7:05 am |
RNS |
Lynparza approved in US for early breast cancer |
| 14th Mar 2022 7:00 am |
RNS |
Update on US review of Fasenra in nasal polyps |
| 9th Mar 2022 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 7th Mar 2022 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 1st Mar 2022 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 1st Mar 2022 3:00 pm |
RNS |
Total Voting Rights |
| 1st Mar 2022 7:00 am |
RNS |
AstraZeneca and Neurimmune close deal for NI006 |
| 23rd Feb 2022 7:00 am |
RNS |
Filing of Form 20-F with SEC |
| 22nd Feb 2022 11:00 am |
RNS |
Chair succession planning update and Annual Report |
| 21st Feb 2022 7:00 am |
RNS |
Enhertu improves PFS and OS in HER2-low BC |
| 16th Feb 2022 7:00 am |
RNS |
Saphnelo approved in EU for SLE |
| 15th Feb 2022 7:00 am |
RNS |
Lynparza combo delays progression risk in prostate |
| 11th Feb 2022 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 10th Feb 2022 7:00 am |
RNS |
AZN: Full year and Q4 2021 results |
| 1st Feb 2022 3:00 pm |
RNS |
Total Voting Rights |
| 19th Jan 2022 7:05 am |
RNS |
Imfinzi improves survival in biliary tract cancer |
| 19th Jan 2022 7:00 am |
RNS |
Imfinzi combo shows unprecedented survival in HCC |
| 17th Jan 2022 7:00 am |
RNS |
Enhertu granted Priority Review for breast cancer |
| 7th Jan 2022 7:00 am |
RNS |
AstraZeneca and Neurimmune sign deal for NI006 |
| 5th Jan 2022 7:00 am |
RNS |
Transfer of rights to Eklira, Duaklir completed |
| 4th Jan 2022 3:00 pm |
RNS |
Total Voting Rights |
| 29th Dec 2021 7:00 am |
RNS |
AstraZeneca and Ionis close eplontersen deal |
| 21st Dec 2021 7:00 am |
RNS |
Ultomiris accepted for FDA Priority Review for gMG |
| 20th Dec 2021 7:05 am |
RNS |
Tezspire approved in the US for severe asthma |
